AU8446891A - Lymphokine 154 - Google Patents
Lymphokine 154Info
- Publication number
- AU8446891A AU8446891A AU84468/91A AU8446891A AU8446891A AU 8446891 A AU8446891 A AU 8446891A AU 84468/91 A AU84468/91 A AU 84468/91A AU 8446891 A AU8446891 A AU 8446891A AU 8446891 A AU8446891 A AU 8446891A
- Authority
- AU
- Australia
- Prior art keywords
- protein
- present
- sequence given
- dna segment
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 108090000623 proteins and genes Proteins 0.000 claims description 54
- 102000004169 proteins and genes Human genes 0.000 claims description 46
- 108020004414 DNA Proteins 0.000 claims description 21
- 150000001413 amino acids Chemical class 0.000 claims description 10
- 239000013598 vector Substances 0.000 claims description 8
- 108020004511 Recombinant DNA Proteins 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims description 4
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims description 4
- 238000012258 culturing Methods 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 235000018102 proteins Nutrition 0.000 description 34
- 210000004027 cell Anatomy 0.000 description 17
- 210000001744 T-lymphocyte Anatomy 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 239000002299 complementary DNA Substances 0.000 description 11
- 102000008072 Lymphokines Human genes 0.000 description 9
- 108010074338 Lymphokines Proteins 0.000 description 9
- 102000004196 processed proteins & peptides Human genes 0.000 description 8
- 108090000765 processed proteins & peptides Proteins 0.000 description 8
- 229920001184 polypeptide Polymers 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 108020004999 messenger RNA Proteins 0.000 description 6
- 210000000987 immune system Anatomy 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- PHEDXBVPIONUQT-UHFFFAOYSA-N Cocarcinogen A1 Natural products CCCCCCCCCCCCCC(=O)OC1C(C)C2(O)C3C=C(C)C(=O)C3(O)CC(CO)=CC2C2C1(OC(C)=O)C2(C)C PHEDXBVPIONUQT-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- YPHMISFOHDHNIV-FSZOTQKASA-N cycloheximide Chemical compound C1[C@@H](C)C[C@H](C)C(=O)[C@@H]1[C@H](O)CC1CC(=O)NC(=O)C1 YPHMISFOHDHNIV-FSZOTQKASA-N 0.000 description 4
- 150000007523 nucleic acids Chemical group 0.000 description 4
- PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 4
- 108700026244 Open Reading Frames Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 235000018417 cysteine Nutrition 0.000 description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 239000003226 mitogen Substances 0.000 description 3
- 210000005259 peripheral blood Anatomy 0.000 description 3
- 239000011886 peripheral blood Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 101150094567 154 gene Proteins 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 241001559589 Cullen Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 235000019687 Lamb Nutrition 0.000 description 1
- 108090000143 Mouse Proteins Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 230000002141 anti-parasite Effects 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 108010028263 bacteriophage T3 RNA polymerase Proteins 0.000 description 1
- 108010058966 bacteriophage T7 induced DNA polymerase Proteins 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- FFYPMLJYZAEMQB-UHFFFAOYSA-N diethyl pyrocarbonate Chemical compound CCOC(=O)OC(=O)OCC FFYPMLJYZAEMQB-UHFFFAOYSA-N 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 230000002297 mitogenic effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000000164 protein isolation Methods 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Description
LYMPHOKINE 154
BACKGROUND OF THE INVENTION Field of the Invention
The present invention relates to secreted proteins (lymphokines) produced by activated T lymphocytes. In particular, the present invention relates to lymphokine 154. Background Information
Quiescent non-dividing T lymphocytes respond to antigen and mitogen stimulation by the activation of cellular genes which are thought to control events that lead to cell proliferation and the expression of a differ¬ entiated phenotype. Treatment of human peripheral blood T cells with the mitogenic combination of phytohemmagglutin (PHA) and phorbol 12-myristate 13-acetate (PMA) appears to mimic the effects of antigen plus antigen presenting cells in vivo. These two agents are known to induce the expres¬ sion of genes which are important for progression through the cell cycle (Reed et al., Proc. Natl. Acad. Sci. USA. 83:3982, 1986).
T lymphocyte activation further induces genes producing secreted factors that direct the growth and differentiation of many cell types, predominantly, but not exclusively, those of the immune system (Dumonde et al., Nature. 224:38f 1969; Mosmann, T.R. "Helper T cells and their lymphokines." T cells. Feld ann, Lamb and Owen ed. 1988 John Wiley and Sons, New York; Rocklin et al. Adv. Immunol. 29:55, 1980). Culture supernatants from activat¬ ed T cells display multiple biological activities includ- ing T cell growth (Taniguchi et al., Nature. 302:305, 1983), B cell growth and differentiation (Namen et al., Nature. 333:571, 1988; Campbell et al., Proc. Natl. Acad. Sci. USA. 84:6629, 1987; Hirano et al., Nature, 324:73, 1986; Yokota et al., Proc. Natl. Acad. Sci. USA. 83:5894, 1986), anti-viral activity (Gray et al., Nature. 295:503, 1982) , activation of cells involved in inflammation (Yoshimura et al., Proc. Natl. Acad. Sci. USA. 84:9233, 1987) , and hematopoietic cell precursor growth and
maturation (Yang et al., Cell. 47:3, 1986). Numerous lymphokines and cytokines including IL-2 through IL-8 (Campbell et al., Proc. Natl. Acad. Sci. USA. 84:6629, 1987; Hirano et al., Nature. 324:73, 1986; Namen et al. , Nature. 333:571, 1988; Taniguchi et al. , Nature. 302:305, 1983; Yang et al., Cell. 47:3, 1986; Yokota et al. , Proc. Natl. Acad. Sci. USA. 83:5894, 1986; Yoshimura et al., Proc. Natl. Acad. Sci. USA. 84:9233, 1987), IFN-γ (Gray et al., Nature. 295:503, 1982), GM-CSF (Wong et al., Science. 228:810, 1985), TNF (Cuturi et al., J. Exp. Med. 165:1581, 1987), LT (Cuturi et al., J. Exp. Med. 165:1581, 1987) and others have been identified, purified and the genes encoding them have subsequently been molecu¬ larly cloned. The cloned genes have proven to be immense- ly useful for the generation of pure recombinant proteins which can be tested for biological functions in the absence of other secreted products. In this way, it has been possible to assign functions unambiguously to indi¬ vidual proteins. Of the numerous lymphokines that have been de¬ scribed, each has its own unique spectrum of biological properties. Although many lymphokines are being developed for clinical utility, most lymphokines act on such complex biological systems as to effect a part of the desired result. Thus, new lymphokines not only present the potential for entirely new spectrums of biological activities, but also could act synergistically with previously described products to effect the overall efficacy of the treatment. SUMMARY OF THE INVENTION
Accordingly, it is an object of the present invention to provide a newly identified lymphokine.
In one embodiment, the present invention relates to a DNA segment encoding protein 154. In another embodiment, the present invention relates to protein 154 substantially free of proteins with which it is normally associated.
In a further embodiment, the present invention
relates to a recombinantly produced or chemically synthe¬ sized protein having all, or a unique portion of the amino acid sequence given in Figure 2.
In another embodiment, the present invention relates to a recombinant DNA construct and to host cells transformed therewith. The DNA construct comprises a DNA segment of the present invention encoding protein 154 and a vector.
In a further embodiment, the present invention relates to a method of producing recombinant protein 154 which comprises culturing host cells of the present invention, in a manner allowing expression of protein 154 encoded therein and isolating the protein.
In yet another embodiment, the present invention relates to an antibody specific for protein 154.
BRIEF DESCRIPTION OF THE DRAWINGS Various other objects and advantages of the present invention will become apparent from the following description of the invention and the figures wherein: Figures 1A, IB and 1C show the nucleotide sequence of the pAT154 cDNA.
Figure 2 shows the putative amino acid sequence of the longest open reading frame of the pAT154 cDNA. The classical hydrophobic leader region contained in the protein is underlined.
Figure 3 shows the hydrophobicity plot of the protein 154.
Figure 4 demonstrates in vitro transcription of a full-length cDNA clone followed by in vitro translation and SDS polyacrylamide gel electrophoresis (SDS PAGE) . The first two lanes are low molecular weight and high molecular weight standards, respectively. The arrow points to the 154 translated protein with a molecular weight of approximately 15 kd. DETAILED DESCRIPTION OF THE INVENTION
One approach to characterizing additional biologi¬ cal activities in supernatants of activated T cells, which activities may be mediated by unidentified proteins, is to
directly identify genes that are expressed in the acti¬ vated T cells, the protein products of which have struc¬ tural features suggesting they are secretory peptides. With this approach, the present inventors have isolated more than 60 genes that are induced in human peripheral blood T cells by mitogens (Zipfel et al. , Mol. Cell. Biol. 9:1034-1040, 1989) . Of these clones, the inventors have fully characterized the 154 gene encoding a lymphokine.
Accordingly, the present invention relates to a DNA segment encoding all, or a unique portion, of protein 154 (lymphokine 154) and to the protein (or polypeptides) encoded therein, or allelic variations thereof. The present invention relates, in particular, to the human protein 154 and to the equivalent protein in other spe- cies. For example, the mouse protein 154 which has been cloned and partially sequenced by the present inventors. A "unique portion" as used herein is defined as consisting of at least five (or six) amino acids, or correspondingly, at least 15 (or 18) nucleotides) . The present invention relates to a DNA segment that encodes the entire amino acid sequence given in Figure 2 (such as, for example, the DNA segment pAT154 given in Figures 1A, IB and 1C) , or any unique portion thereof. DNA segments to which the invention relates also include those encoding substantially the same protein as that of Figure 2, which includes, for example, allelic forms thereof or the mouse lymphokine 154. DNA segments of the present invention can be used as probes for detect¬ ing the presence of DNA or RNA encoding lymphokine 154 in a sample.
The present invention also relates to nucleotide sequences complementary to the segments referenced above.
The present invention further relates to protein 154 substantially free of proteins with which it is normally associated. The lymphokine 154 can be purified by one skilled in the art using protocols known in the art for protein purification. The present invention also relates to the lymphokine 154 and to peptide fragments
thereof which are chemically synthesized or recombinantly produced.
The protein and polypeptides the present invention can be used as antigens, in protocols known in the art, to produce antibodies thereto, both monoclonal and poly- clonal. For example, a polypsptide having an amino acid sequence corresponding to an epitope of the sequence given in Figure 2 (or an allelic variation thereof) , can be used to generate antibodies specific for lymphokine 154. Such antibodies can be used in bioassays to detect the presence of protein 154 in samples, such as biological samples.
The present invention further relates to a recom¬ binant DNA construct and to a host cell transformed therewith. Using standard methodology known in the art, a recombinant DNA construct comprising the above-described DNA segment encoding all, or a unique portion of lymphokine 154 and a vector can be constructed without undue experimentation. Suitable vectors for use in the present invention include, but are not limited to, the bacterial vector pET-3 (Studier et al. , Methods in Enzymology 185: in press, 1990) , the yeast vector YRpRl (Rymond et al., Gene 25: 249, 1983), and the eukaryotic vector pBC12-CMV (Cullen, Cell 46: 973, 1986). The DNA segment can be isolated for activated T-cells or take the form of a cDNA clone. The DNA segment can be present in the vector operably linked to regulatory elements, includ¬ ing, for example a promoter. The host cell can be pro- karyotic (such as bacterial) , lower eukaryotic (such as fungal, including yeast) or higher eukaryotic (such as mammalian) .
Host cells of the present invention can be used to generate recombinantly produced lymphokine 154. The host cells can be cultured under conditions such that protein 154 (or a unique polypeptide thereof) encoded in the construct is expressed. The expressed protein can be isolated using standard protein isolation protocols.
The present invention also relates to a membrane bound form of the lymphokine 154 and host cells expressing
such on their surfaces. As one skilled in the art will appreciate, the membrane form of protein 154 can be generated with the addition of a transmembrane anchor encoding sequence on the DNA segment encoding the protein. Furthermore, host cells transformed with a recombinant DNA construct encoding such a DNA segment will express protein 154 on their surface.
Lymphokines provide a wide array of activities relating to the immune system. Lymphokine activities range from recruiting cells, such as macrophages, to specific sites to mount an effective immune response, to fighting viral infections. Lymphokine 154 of the present invention may provide such activities and therefore could be used in various treatment regimens. For example, the protein or polypeptide of the present invention may exert cytotoxic effects on certain cells such as tumor cells and could therefore be used in the treatment of cancer. Further, the protein or polypep¬ tide of the present invention may have anti-viral and/or anti-parasitic activity (such as the activity of the lymphokine -interferon) , in which case the present invention could be used in the treatment of viral or parasitic infections. Lymphokine 154 may also effect the growth and/or differentiation of cells, particularly, hematopoietic cells (an activity displayed by several of the interleukin lymphokines) . Such activity would be useful in the treatment of diseases which adversely affect and/or deplete cells of the immune system. In addition, lymphokine 154 may have the ability to augment the immune system which would allow the protein or polypeptides of the present invention to be used, for example, to detect rejection of a transplanted organ by monitoring the presence of the protein or polypeptide in the blood or urine of the transplant patient. An increase in the amount of protein or polypeptide in the biological fluid of the patient could be an early indication that the immune system is rejecting the foreign organ.
The following non-limiting examples are provided
to aid in the understanding of the present invention and do not restrict the scope of the invention.
EXAMPLES CLONING. CDNA clones of pAT154 were originally isolated from a previously described subtractive hybridization library (Zipfel et al., Mol. Cell. Biol. 9:1041-1048, 1989) . Additional clones were isolated from a λZap library (Stratagene) (Short et al., Nuc. Acids. Res. 16:7583-7600, 1988), or from an oligo dT primed λgtlO library made following the Guebler-Hoffman method (Gubler et al., Gene. 25:263, 1983).
Br_^fly, human peripheral blood T cells were isolated f om whole blood and stimulated for 4.5 hours in vitro using the mitogenic agents phytohemmagglutin (PHA) (1 μg/ml) and phorbol 12-myristate 13-acetate (PMA) (20 ng/ml) in the presence of cycloheximide (CX) (10 μg/ml) . cDNA synthesized from the mRNA was cloned into λgtlO or λZap and screened using a 453 bp probe of pAT154 original- ly isolated from the subtractive hybridization library. A total of seven clones covering the length of the mRNA were isolated, mapped and sequenced. SEQUENCE ANALYSIS
The nucleic acid sequence was determined on both st ands of pAT154 cDNA's by the Sanger dideoxy chain termination method (Sanger et al., Pro. Natl. Acad. Sci.
USA. 77:5463-5467, 1977) (See Figures 1A, IB and 1C) .
Two micrograms of pBlueScript (Stratagene) containing 154 cDNA inserts sre alkaline denatured in a final concentra- tion of 0.2N NaOH for 5 min. at room temperature. The DNA was neutralized with 5M NH40Ac and ethanol precipitated in
3 volumes of -70°C ethanol and placed on dry ice for 10 min. The DNA was pelleted and resuspended. Sequencing reactions were performed according to manufacturer's instructions using the USB Sequenase II Kit. Elongation and termination reactions were carried out in the presence of 10% dimethyl sulfoxide (DMSO) (Winship, P.R., Nuc.
Acid. Res. 17:1266, 1989). Sequencing reactions were
heated above 80°C for 4 min and electrophoresed on 8% denaturing polyacrylamide gels containing 8M urea at a constant 65 W. The nucleic acid sequence was determined after exposure against autoradiographic film. Storage and analysis of the nucleic acid sequence was performed using the computer package MicroGenie (Beckman) (Queen et al. , Nuc. Acids. Res. 12:581-599, 1984). The putative amino acid sequence was determined (see Figure 2) and shown to contain a classical hydrophobic leader region but no transme brane anchor indicating that the pAT154 protein is secreted (see Figure 3) . COMPUTER AIDED SEARCH ANALYSIS.
The computer package GenBank (V.63 + updates through 5/90) was utilized to search the nucleic acid and protein databanks for statistically relevant homologies in the published literature to the pAT154 cDNA and amino acid sequences. No sequences having significant homology with pAT154 were found. IN VITRO TRANSCRIPTION OF 154 OPEN READING FRAME. A total of 10 μg pAT154 cDNA containing the 154 open reading frame was linearized by a Cla I digestion of the pBlueScript's Multicloning site. The final digest was adjusted to 0.5 M NaCl and Proteinase K (1 mg/ml) treated for 30 min. at 37°C. The cDNA was treated twice with 1:1 phenol/chloroform and ethanol precipitated and dried. The resulting pellet was resuspended at a final concentration of 0.5 μg/μl using diethyl pyrocarbonate treated H20. In vitro transcription of the 154 cDNA utilizing T3RNA polymerase (Stratagene) was performed according to manu- facturer's instructions. A 1 μl aliquot of the mRNA was qualitatively tested by electrophoresis of a lxTBE 1% agarose gel for 10 min. IN VITRO TRANSLATION OF 154 PROTEIN.
The 154 mRNA was translated utilizing a rabbit reticulolysate system (Promega) . Five microliters of 154 mRNA (representing 20% of the total mRNA transcribed) was mixed with rabbit reticulolysate, amino acids (minus cysteine) and cysteine, L-[35S] (NEN) according to the
Promega protocol. This mixture was incubated for 60 min. at 30°C. Free label was removed from the final translate by dialysis (EmproTech Prodialyzer) against 0.1 M NH4HC03 overnight at 4°C. Samples were lyophilized and resus- pended in a 50 μl volume of H20 containing 20% 5x sample buffer and were boiled for 5 min. Cysteine, L-[35S] incorporation was analyzed by electrophoresing translates on a 12.5% polyacrylamide gel at 110V constant and expos¬ ing the gel against autoradiographic film (see Figure 4) . All publications mentioned hereinabove are hereby incorporated by reference.
The foregoing invention has been described in detail for purposes of clarity and understanding. Howev¬ er, it will be appreciated that those skilled in the art, upon consideration of this disclosure, may make modifica¬ tions and improvements without departing from the true scope of this invention.
Claims
1. A isolated DNA segment encoding protein 154.
2. The DNA segment according to claim 1 which encodes the amino acid sequence given in Figure 2.
3. The DNA segment according to claim 1, which encodes at least 5 amino acids of the sequence given in Figure 2.
4. A secreted protein 154 substantially free of proteins with which it is normally associated.
5. The protein according to claim 4 having the amino acid sequence given in Figure 2, or an allelic variation thereof.
6. The protein according to claim 4 having at least 5 amino acids of the sequence given in Figure 2.
7. A recombinantly produced protein having the amino acid sequence given in Figure 2, or an allelic variation thereof.
8. A recombinant DNA construct comprising: i) said DNA segment according to claim 1; and ii) a vector.
9. A host cell stably transformed with said recombinant DNA construct according to claim 8 in a manner allowing expression of said protein encoded in said recombinant DNA construct.
10. A method of producing recombinant protein 154 comprising culturing said host cells according to claim 9, in a manner allowing expression of said protein and isolating said protein.
11. An antibody specific for protein 154.
12. The antibody according to claim 11 which is monoclonal.
13. The antibody according to claim 11 which is polyclonal.
14. Use of the last cell according to claim 9 for the preparation of recombinant protein 154.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US566108 | 1983-12-27 | ||
| US56610890A | 1990-08-13 | 1990-08-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU8446891A true AU8446891A (en) | 1992-03-17 |
Family
ID=24261524
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU84468/91A Abandoned AU8446891A (en) | 1990-08-13 | 1991-08-13 | Lymphokine 154 |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP0544743A4 (en) |
| JP (1) | JPH05508778A (en) |
| AU (1) | AU8446891A (en) |
| CA (1) | CA2089258A1 (en) |
| WO (1) | WO1992003466A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0948531A1 (en) * | 1996-12-11 | 1999-10-13 | Chiron Corporation | Secreted human proteins |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL92685A0 (en) * | 1988-12-16 | 1990-09-17 | Us Commerce | Dna encoding lymphokine/cytokine like proteins,cells transformed thereby and production of said proteins and antibodies against them |
-
1991
- 1991-08-13 CA CA002089258A patent/CA2089258A1/en not_active Abandoned
- 1991-08-13 AU AU84468/91A patent/AU8446891A/en not_active Abandoned
- 1991-08-13 JP JP91514525A patent/JPH05508778A/en active Pending
- 1991-08-13 EP EP19910914922 patent/EP0544743A4/en not_active Withdrawn
- 1991-08-13 WO PCT/US1991/005749 patent/WO1992003466A1/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| JPH05508778A (en) | 1993-12-09 |
| CA2089258A1 (en) | 1992-02-14 |
| WO1992003466A1 (en) | 1992-03-05 |
| EP0544743A1 (en) | 1993-06-09 |
| EP0544743A4 (en) | 1994-05-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Matsushima et al. | Molecular cloning of a human monocyte-derived neutrophil chemotactic factor (MDNCF) and the induction of MDNCF mRNA by interleukin 1 and tumor necrosis factor. | |
| Gimbrone Jr et al. | Endothelial interleukin-8: a novel inhibitor of leukocyte-endothelial interactions | |
| Tanabe et al. | Identification of a new mouse beta-chemokine, thymus-derived chemotactic agent 4, with activity on T lymphocytes and mesangial cells. | |
| JP2515308B2 (en) | Human immune interferon | |
| KR100687388B1 (en) | Interleukin-18 binding protein, preparation method thereof and use thereof | |
| EP0569687A1 (en) | Human IL-1 cDNA sequences encoding biologically-active human IL-1 proteins | |
| JP2952750B2 (en) | Monoclonal antibody | |
| Brieland et al. | Effect of acute inflammatory lung injury on the expression of monocyte chemoattractant protein-i (MCP-i) in rat pulmonary alveolar macrophages | |
| WO1991017184A1 (en) | Modified interleukin-1 inhibitors | |
| CA2332817C (en) | Il-6 antagonist peptides | |
| CS395391A3 (en) | Homogeneous human interleukin 2, process of its preparation and apharmaceutical composition based thereon | |
| CA2441636A1 (en) | Natural killer stimulatory factor | |
| JP3192651B2 (en) | Interleukin-1 inhibitor | |
| EP0491878B1 (en) | Compositions for the inhibition of protein hormone formation and uses thereof | |
| JP2805008B2 (en) | Bioactive human IL-1 protein | |
| US20070270329A1 (en) | Human derived monocyte attracting purified protein product useful in a method of treating infection and neoplasms in a human body, and the cloning of full length cDNA thereof | |
| KR19980079551A (en) | Polypeptide | |
| JP2001518296A (en) | Amino-terminal truncated MCP-2 as chemokine antagonist | |
| KR100270348B1 (en) | Transcription factor AFP | |
| JP2003047483A (en) | Interleukin-6 splice mutant | |
| EP0273373A2 (en) | Novel peptides and production thereof | |
| EP0355202A1 (en) | Factor regulating gene expression | |
| AU8446891A (en) | Lymphokine 154 | |
| US5434247A (en) | Peptides for inducing monocyte cytotoxicity in diagnostics | |
| EP0256042A1 (en) | Interleukin |